| NCT ID | NCT07373444 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Westlake University |
| Condition | Aging |
| Study Type | OBSERVATIONAL |
| Enrollment | 2,800 participants |
| Start Date | 2026-06-03 |
| Primary Completion | 2030-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 2,800 participants in total. It began in 2026-06-03 with a primary completion date of 2030-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The Westlake Ageing Cohort (WeAC) is a longitudinal cohort study conducted in Hangzhou, Zhejiang Province, China. The investigators aim to enroll 2,800 participants aged 55 years and older for long-term follow-up. The population will include individuals with neurodegenerative diseases or those at the prodromal stage of cognitive impairment, as well as healthy middle-aged and older adults serving as controls. The investigators will collect their sociodemographic, dietary, lifestyle, clinical, and neuroimaging data, as well as biological samples.
Eligibility Criteria
Inclusion Criteria: 1. Age between 55 and 90 years (inclusive) at baseline. 2. Availability of a companion capable of providing independent functional assessments and fluent in Chinese. 3. Willingness and ability to regularly complete required surveys and physical examinations as per study protocol. 4. MMSE scores were required to be 24-30 (inclusive) for healthy controls and MCI; and 20-24 (inclusive) for AD and DLB/PDD patients. 5. Healthy controls: CDR = 0, memory box = 0. MCI: CDR = 0.5, memory box ≥ 0.5. AD: CDR = 0.5 or 1. The DLB/PDD meets the core features of diagnosis. 6. Healthy controls exhibit no significant cognitive or functional decline. Patients with MCI have objective cognitive impairment not sufficient for an AD diagnosis. AD patients fulfill the NINCDS-ADRDA criteria. DLB/PDD patients meet their respective international consensus diagnostic criteria. Other neurodegenerative diseases meet the diagnostic criteria. Exclusion Criteria: 1. Participants with major medical or neuropsychiatric conditions unrelated to the study purposes were excluded. These included, but were not limited to, psychiatric disorders, cancer, infectious diseases, structural brain abnormalities, and epilepsy. 2. Current use of psychoactive medications or any other drugs that may affect the study. 3. Participants with cardiac pacemakers, artificial heart valves, or metallic implants in the eyes, skin, or any other part of the body. 4. Participants with any other diseases that may affect the study.
Contact & Investigator
Ju-Sheng Zheng, PhD
PRINCIPAL INVESTIGATOR
Westlake University
Frequently Asked Questions
Who can join the NCT07373444 clinical trial?
This trial is open to participants of all sexes, aged 55 Years or older, up to 90 Years, studying Aging. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07373444 currently recruiting?
Yes, NCT07373444 is actively recruiting participants. Contact the research team at zhengjusheng@westlake.edu.cn for enrollment information.
Where is the NCT07373444 trial being conducted?
This trial is being conducted at Hangzhou, China, Hangzhou, China.
Who is sponsoring the NCT07373444 clinical trial?
NCT07373444 is sponsored by Westlake University. The principal investigator is Ju-Sheng Zheng, PhD at Westlake University. The trial plans to enroll 2,800 participants.